VanEck Associates’s CME Group CME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.6M Sell
79,865
-3,218
-4% -$890K 0.01% 471
2026
Q1
$24.5M Buy
83,083
+2,018
+2% +$599K 0.02% 399
2025
Q4
$22.1M Buy
81,065
+64,519
+390% +$17.5M 0.02% 370
2025
Q3
$4.47M Buy
16,546
+784
+5% +$213K ﹤0.01% 797
2025
Q2
$4.34M Sell
15,762
-27,242
-63% -$7.41M ﹤0.01% 777
2025
Q1
$11.4M Sell
43,004
-4,799
-10% -$1.18M 0.01% 441
2024
Q4
$11.1M Sell
47,803
-24,705
-34% -$5.68M 0.01% 438
2024
Q3
$16.5M Sell
72,508
-181
-0.2% -$37.5K 0.02% 350
2024
Q2
$14.3M Sell
72,689
-7,258
-9% -$1.5M 0.02% 342
2024
Q1
$17.2M Sell
79,947
-4,398
-5% -$924K 0.03% 302
2023
Q4
$17.8M Sell
84,345
-12,176
-13% -$2.6M 0.03% 274
2023
Q3
$19.3M Sell
96,521
-3,009
-3% -$598K 0.04% 246
2023
Q2
$18.4M Buy
99,530
+6,559
+7% +$1.21M 0.04% 258
2023
Q1
$17.8M Buy
92,971
+16,501
+22% +$2.98M 0.04% 257
2022
Q4
$12.9M Buy
76,470
+32,348
+73% +$5.62M 0.03% 301
2022
Q3
$7.82M Buy
44,122
+1,821
+4% +$360K 0.02% 355
2022
Q2
$8.66M Buy
42,301
+935
+2% +$198K 0.02% 355
2022
Q1
$9.84M Sell
41,366
-3,179
-7% -$747K 0.02% 365
2021
Q4
$10.2M Buy
44,545
+32,169
+260% +$7.08M 0.02% 372
2021
Q3
$2.39M Buy
12,376
+2,593
+27% +$525K 0.01% 630
2021
Q2
$2.08M Sell
9,783
-573
-6% -$121K ﹤0.01% 659
2021
Q1
$2.12M Buy
10,356
+2,792
+37% +$550K 0.01% 599
2020
Q4
$1.38M Sell
7,564
-177
-2% -$30.1K ﹤0.01% 609
2020
Q3
$1.29M Sell
7,741
-9,789
-56% -$1.65M ﹤0.01% 579
2020
Q2
$2.85M Sell
17,530
-5,386
-24% -$965K 0.01% 430
2020
Q1
$3.96M Sell
22,916
-9,682
-30% -$1.93M 0.02% 358
2019
Q4
$6.54M Buy
32,598
+1,385
+4% +$284K 0.03% 325
2019
Q3
$6.6M Buy
31,213
+1,001
+3% +$209K 0.03% 286
2019
Q2
$5.86M Buy
30,212
+2,797
+10% +$516K 0.03% 295
2019
Q1
$4.51M Buy
27,415
+23,224
+554% +$4.11M 0.02% 346
2018
Q4
$788K Buy
4,191
+143
+4% +$26.4K ﹤0.01% 574
2018
Q3
$689K Sell
4,048
-54
-1% -$9.09K ﹤0.01% 638
2018
Q2
$672K Buy
+4,102
New +$670K ﹤0.01% 630

Other funds holding CME

VanEck Associates's CME Position: Q2 2026 in Review

VanEck Associates reduced its CME Group (CME) stake by 3.9% in Q2 2026, selling an estimated $890K and leaving 79,865 shares worth $17.6M. The position accounts for 0.01% of the portfolio, ranked #471.

VanEck Associates first reported a position in CME in Q2 2018 and has held it in 33 quarters since. The position peaked at $24.5M in Q1 2026. 1,694 funds tracked by Wall St. Rank hold CME as of Q2 2026.

  • VanEck Associates held 79,865 shares of CME Group worth $17.6M as of Q2 2026.
  • VanEck Associates sold 3,218 CME Group shares in Q2 2026, an estimated $890K.
  • CME Group made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #471 holding.
  • VanEck Associates first reported a position in CME Group in Q2 2018 and has held it in 33 quarters since.
  • VanEck Associates's CME Group position peaked at $24.5M in Q1 2026.
  • 1,694 funds tracked by Wall St. Rank held CME Group as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.